HOLX · Hologic Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.05B | $1.02B | $1.01B | $1.02B | $1.01B | $1.02B | $1.01B | $984.40M | $1.03B | $1.07B |
| Cost of Revenue | $417.60M | - | - | - | - | $308.60M | $307.20M | $291.00M | $292.10M | $296.20M |
| Gross Profit | $586.40M | $576.60M | $377.30M | $580.50M | $560.30M | $542.30M | $567.50M | $367.50M | $585.80M | $617.90M |
| R&D | $60.50M | $61.40M | $61.50M | $60.30M | $64.10M | $74.60M | $66.80M | $72.60M | $74.00M | $74.80M |
| SG&A | $127.80M | $99.10M | $119.70M | $115.70M | $94.00M | $100.40M | $111.80M | $90.20M | $100.80M | $108.50M |
| Total Operating Expenses | $349.40M | $322.00M | $384.30M | $350.70M | $316.30M | $331.90M | $369.30M | $366.10M | $313.70M | $355.50M |
| D&A | $26.30M | - | - | $23.30M | - | - | $29.60M | - | - | $22.70M |
| Operating Income | $237.00M | $254.60M | ($7.00M) | $229.80M | $244.00M | $210.40M | $198.20M | $1.40M | $272.10M | $262.40M |
| Interest Expense | $30.50M | $28.90M | $29.10M | $30.50M | $31.90M | $32.30M | $26.00M | $27.70M | $27.20M | $28.10M |
| Income Tax | $50.60M | $40.10M | ($11.10M) | $46.50M | $46.20M | $41.60M | ($55.20M) | $52.60M | $60.80M | $51.70M |
| Net Income | $187.20M | $194.90M | ($17.40M) | $178.60M | $194.50M | $169.90M | $90.60M | ($40.50M) | $218.50M | $187.40M |
| EPS - Basic | $0.80 | $0.87 | ($0.08) | $0.87 | $0.83 | $0.72 | $1.03 | ($0.16) | $0.88 | $0.76 |
| EPS - Diluted | $0.79 | $0.86 | ($0.08) | $0.87 | $0.82 | $0.72 | $1.03 | ($0.16) | $0.87 | $0.75 |
Balance Sheet
| Line item | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.17B | $1.96B | $1.43B | $1.78B | $2.16B | $2.18B | $1.93B | $2.72B | $2.58B | $2.44B |
| Accounts Receivable | $584.20M | $600.80M | $644.40M | $631.40M | $600.40M | $647.10M | $670.90M | $625.60M | $714.00M | $673.80M |
| Inventory | $688.50M | $679.40M | $716.70M | $707.10M | $679.80M | $649.20M | $633.60M | $617.60M | $687.60M | $677.70M |
| Accounts Payable | $201.10M | $193.40M | $208.60M | $236.70M | $203.80M | $202.50M | $183.80M | $175.20M | $187.40M | $201.80M |
| Current Assets | $3.84B | $3.67B | $3.21B | $3.49B | $3.82B | $3.79B | $3.49B | $4.18B | $4.21B | $4.02B |
| Total Assets | $9.18B | $9.01B | $8.55B | $8.73B | $9.16B | $8.71B | $8.47B | $9.14B | $9.45B | $9.29B |
| Current Liabilities | $951.30M | $977.20M | $989.70M | $1.00B | $1.04B | $954.60M | $899.00M | $1.21B | $955.00M | $956.20M |
| Long-term Debt | $2.50B | $2.50B | $2.46B | $2.48B | $2.50B | $2.51B | $2.52B | $2.53B | $2.80B | $2.81B |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | $5.25B | $5.05B | $4.62B | $4.77B | $5.13B | $4.84B | $4.65B | $5.02B | $5.30B | $5.09B |
| Retained Earnings | $3.59B | $3.41B | $3.03B | $3.05B | $2.85B | $2.47B | $2.30B | $2.06B | $2.01B | $1.79B |
Cash Flow
| Line item | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $229.90M | - | - | $189.30M | - | - | $220.00M | - | - | $253.40M |
| Investing Cash Flow | ($12.10M) | - | - | ($22.00M) | - | - | ($104.20M) | - | - | ($41.00M) |
| Financing Cash Flow | ($10.70M) | - | - | ($537.00M) | - | - | ($943.80M) | - | - | ($113.50M) |
| CapEx | $14.70M | $34.90M | $40.30M | $22.70M | $33.90M | $28.00M | $38.00M | $36.50M | $32.10M | $29.10M |
| Free Cash Flow | $215.20M | - | - | $166.60M | - | - | $182.00M | - | - | $224.30M |
Ratios
| Metric | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 56.0% | 56.3% | 37.5% | 56.8% | 55.4% | 53.3% | 56.0% | 37.3% | 57.1% | 57.5% |
| Operating margin | 22.6% | 24.9% | -0.7% | 22.5% | 24.1% | 20.7% | 19.6% | 0.1% | 26.5% | 24.4% |
| EBITDA margin | 25.1% | - | - | 24.8% | - | - | 22.5% | - | - | 26.5% |
| Net margin | 17.9% | 19.0% | -1.7% | 17.5% | 19.2% | 16.7% | 8.9% | -4.1% | 21.3% | 17.4% |
| Free cash flow margin | 20.5% | - | - | 16.3% | - | - | 18.0% | - | - | 20.9% |
| FCF / Net income | 1.15 | - | - | 0.93 | - | - | 2.01 | - | - | 1.20 |
| R&D / Revenue | 5.8% | 6.0% | 6.1% | 5.9% | 6.3% | 7.3% | 6.6% | 7.4% | 7.2% | 7.0% |
| SG&A / Revenue | 12.2% | 9.7% | 11.9% | 11.3% | 9.3% | 9.9% | 11.0% | 9.2% | 9.8% | 10.1% |
| Effective tax rate | 21.3% | 17.1% | - | 20.7% | 19.2% | 19.7% | -155.9% | 434.7% | 21.8% | 21.6% |
| Return on assets | 2.0% | 2.2% | -0.2% | 2.0% | 2.1% | 1.9% | 1.1% | -0.4% | 2.3% | 2.0% |
| Return on equity | 3.6% | 3.9% | -0.4% | 3.7% | 3.8% | 3.5% | 1.9% | -0.8% | 4.1% | 3.7% |
| Return on invested capital | 2.4% | 2.8% | -0.1% | 2.5% | 2.6% | 2.3% | 2.8% | 0.0% | 2.6% | 2.6% |
| Liquidity | ||||||||||
| Current ratio | 4.04 | 3.75 | 3.24 | 3.49 | 3.69 | 3.97 | 3.89 | 3.47 | 4.41 | 4.21 |
| Quick ratio | 3.32 | 3.06 | 2.52 | 2.78 | 3.03 | 3.29 | 3.18 | 2.95 | 3.69 | 3.50 |
| Cash ratio | 2.28 | 2.01 | 1.44 | 1.78 | 2.08 | 2.28 | 2.15 | 2.26 | 2.70 | 2.55 |
| Leverage | ||||||||||
| Debt / Equity | 0.48 | 0.50 | 0.53 | 0.52 | 0.49 | 0.52 | 0.54 | 0.50 | 0.53 | 0.55 |
| Debt / Assets | 0.27 | 0.28 | 0.29 | 0.28 | 0.27 | 0.29 | 0.30 | 0.28 | 0.30 | 0.30 |
| Debt / EBITDA | 9.51 | - | - | 9.80 | - | - | 11.07 | - | - | 9.84 |
| Interest coverage | 7.8x | 8.8x | -0.2x | 7.5x | 7.6x | 6.5x | 7.6x | 0.1x | 10.0x | 9.3x |
| Equity multiplier | 1.75 | 1.79 | 1.85 | 1.83 | 1.78 | 1.80 | 1.82 | 1.82 | 1.78 | 1.82 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | 0.11 | 0.11 | 0.12 | 0.12 | 0.11 | 0.12 | 0.12 | 0.11 | 0.11 | 0.12 |
| Inventory turnover | 0.61 | - | - | - | - | 0.48 | 0.48 | 0.47 | 0.42 | 0.44 |
| Days sales outstanding | 204d | 214d | 234d | 226d | 217d | 232d | 242d | 232d | 254d | 229d |
| Days inventory outstanding | 602d | - | - | - | - | 768d | 753d | 775d | 859d | 835d |
| Days payable outstanding | 176d | - | - | - | - | 240d | 218d | 220d | 234d | 249d |
| Cash conversion cycle | 630d | - | - | - | - | 760d | 776d | 787d | 879d | 815d |
| Valuation | ||||||||||
| P / E | 94.3x | 78.2x | - | 83.4x | 98.6x | 108.3x | 69.4x | - | 92.8x | 99.7x |
| P / B | 3.2x | 3.0x | 3.0x | 3.5x | 3.7x | 3.8x | 3.7x | 3.4x | 3.8x | 3.7x |
| P / S | 16.1x | 14.8x | 13.8x | 16.5x | 18.9x | 18.2x | 16.9x | 17.4x | 19.6x | 17.4x |
| EV / EBITDA | 65.2x | - | - | 69.3x | - | - | 77.9x | - | - | 66.7x |
| Growth | ||||||||||
| Revenue growth (YoY) | 2.5% | 1.2% | -1.2% | 0.9% | 2.7% | -0.8% | -5.7% | -1.8% | -28.5% | -27.0% |
| Revenue CAGR (3y) | -0.8% | 0.7% | -11.2% | -11.4% | -4.7% | -12.8% | -14.3% | 6.2% | 10.7% | 8.1% |
| Revenue CAGR (5y) | -8.2% | 4.5% | 5.9% | 3.7% | 3.5% | 4.5% | 4.0% | 3.6% | 5.4% | 6.3% |
| Gross profit growth (YoY) | 1.0% | 2.9% | -30.4% | 2.3% | 52.5% | -7.4% | -8.2% | -33.2% | -38.1% | -37.4% |
| Operating income growth (YoY) | 3.1% | 4.3% | - | 15.9% | 17328.6% | -22.7% | -24.5% | -99.5% | -54.2% | -59.1% |
| Net income growth (YoY) | 4.8% | 0.2% | - | 97.1% | - | -22.2% | -51.7% | - | -52.1% | -62.5% |
| EPS growth (YoY) | -9.2% | 4.9% | - | -15.5% | - | -17.2% | 37.3% | - | -51.7% | -61.5% |
| EPS CAGR (3y) | 1.7% | -1.5% | - | -23.6% | -7.6% | -32.9% | -25.6% | - | 34.2% | -19.4% |
| EPS CAGR (5y) | -20.6% | 10.2% | - | -9.5% | 18.6% | - | 23.4% | - | - | -12.4% |
| FCF growth (YoY) | 29.2% | - | - | -8.5% | - | - | -18.9% | - | - | -59.1% |
| FCF CAGR (5y) | -19.0% | - | - | 10.2% | - | - | 13.9% | - | - | 7.1% |
| Book value growth (YoY) | 9.9% | -1.6% | -4.7% | 2.6% | 2.3% | -8.6% | -8.6% | 2.9% | 10.6% | 12.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-09-27.
Business segments
$4.10B totalDiagnostics$1.83B · 44.6%
Breast Health$1.48B · 36.2%
Gyn Surgical$679.80M · 16.6%
Skeletal Health$109.40M · 2.7%
Product / service
$6.60B totalDisposables$2.62B · 39.7%
Molecular Diagnostics$1.03B · 15.6%
Breast Imaging$860.20M · 13.0%
Service$825.50M · 12.5%
Capital Equipment Componentsand Software$638.40M · 9.7%
Cytology Perinatal$296.10M · 4.5%
Interventional Breast Solutions$282.10M · 4.3%
Blood Screening$28.20M · 0.4%
Other Typeof Revenue$18.90M · 0.3%
Geographic
$2.88B totalUS$1.35B · 47.0%
Europe$591.00M · 20.5%
International$474.50M · 16.5%
Asia Pacific$243.30M · 8.4%
Other Geographic Regions$218.30M · 7.6%
Peer comparison
Same SIC group: X-Ray Apparatus & Tubes & Related Irradiation Apparatus
Comparing HOLOGIC INC against the 4 most active filers in the same SIC group.